{"result": "(\"entity\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>EVENT<|>A surgical procedure involving total duodenopancreatectomy, splenectomy, and partial gastrectomy with hepatic and jejunal anastomosis, performed on a patient with pancreatic endocrine carcinoma.)\n##\n(\"entity\"<|>CARCINOMA DE PÁNCREAS ENDOCRINO<|>EVENT<|>A type of cancer diagnosed in the patient, characterized by a 3 cm low-grade tumor located in the head of the pancreas, with lymph node involvement.)\n##\n(\"entity\"<|>NUTRICIÓN INTRAHOSPITALARIA<|>EVENT<|>The provision of nutritional support to the patient during hospitalization, including parenteral nutrition with specific macronutrient composition.)\n##\n(\"entity\"<|>INSULINA<|>EVENT<|>A hormone administered to the patient to manage elevated blood glucose levels during treatment.)\n##\n(\"entity\"<|>ECOGRAFÍA<|>EVENT<|>An ultrasound examination performed to assess the patient's condition, revealing a questionable hypoechoic image in the liver.)\n##\n(\"entity\"<|>TAC<|>EVENT<|>A computed tomography scan used for monitoring the patient's condition, showing normal results at one point.)\n##\n(\"entity\"<|>RNM<|>EVENT<|>A magnetic resonance imaging scan conducted to evaluate the patient's liver lesions and metastasis.)\n##\n(\"entity\"<|>GAMMAGRAFÍA CON OCTREÓTIDE<|>EVENT<|>A specialized imaging test performed to assess the presence of liver lesions and metastasis.)\n##\n(\"entity\"<|>QT ESTREPTOZOTOCINA<|>EVENT<|>A chemotherapy regimen initiated for the patient, involving the administration of streptozotocin.)\n##\n(\"entity\"<|>ADRIMICINA<|>EVENT<|>A chemotherapy drug administered to the patient as part of the treatment plan.)\n##\n(\"entity\"<|>ENFERMEDAD ESTABLE<|>EVENT<|>A status indicating that the patient's condition has stabilized during treatment.)\n##\n(\"relationship\"<|>DUODENOPANCREATECTOMÍA TOTAL<|>CARCINOMA DE PÁNCREAS ENDOCRINO<|>The total duodenopancreatectomy was performed as a treatment for the pancreatic endocrine carcinoma diagnosed in the patient.<|>8)\n##\n(\"relationship\"<|>NUTRICIÓN INTRAHOSPITALARIA<|>INSULINA<|>Nutritional support was provided alongside insulin treatment to manage the patient's hyperglycemia during hospitalization.<|>7)\n##\n(\"relationship\"<|>ECOGRAFÍA<|>TAC<|>Both imaging tests were conducted to monitor the patient's condition and assess the presence of lesions in the liver.<|>6)\n##\n(\"relationship\"<|>RNM<|>GAMMAGRAFÍA CON OCTREÓTIDE<|>Both imaging techniques were used to evaluate the patient's liver lesions and confirm the presence of metastasis.<|>6)\n##\n(\"relationship\"<|>QT ESTREPTOZOTOCINA<|>ADRIMICINA<|>Both chemotherapy treatments were part of the patient's regimen to manage the progression of the disease.<|>7)\n##\n(\"relationship\"<|>CARCINOMA DE PÁNCREAS ENDOCRINO<|>ENFERMEDAD ESTABLE<|>The patient's condition was monitored for stability following treatment for the pancreatic endocrine carcinoma.<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: /1999: DUODENOPANCREATECTOMÍA TOTAL + ESPLENECTOMÍA + GASTRECTOMÍA\n     PARCIAL con anastomosis hepáticoyeyunal y gastroyeyunal (no se vieron LOES hepáticas).\n     AP: CARCINOMA DE PÁNCREAS ENDOCRINO 3 cm, DE BAJO GRADO LOCALIZADO EN\n     CABEZA PANCREÁTICA, 5/7 GANGLIOS AFECTOS. Cromogranina +, inmunorreacción para\n     VIP moderadamente + pero negativa para el resto de hormonas (insulina, glucagón,\n     serotonina, y pp). Índice proliferativo Ki 67 ≤ 1%. Necrosis hemorrágica de vesícula y\n     esplenomegalia congestiva sin malignidad.\n     Nutrición intrahospitalaria. NPT con 17 gr de N2 250 g de glucosa, 75 gr de grasa\n     (LCT/MCT) en 2500 ml3 .\n     Glucemias elevadas que requieren insulina basal s.c. y adición de insulina rápida en\n     bolsa.\n     Se reduce aporte de glucosa en NPT (200 g) y se ajustan dosis de insulina.\n     Afebril, buen estado de hidratación, glucemias 200-250 mg, iones normales, Albúmina 2,1.\n     Seguimiento.\n\n\n\n              18/3/99: asintomático. TAC de control Normal.\n\n\n\n              30/8/99:    paciente asintomático, hiperglucemia controlada con Insulina, en\n     ECOGRAFÍA: imagen hipoecoica dudosa de 9 mm en segmento VIII hepático. Observación.\n\n\n\n              Enero 2000, TAC: imagen parcheada en área pancreática de aspecto fibroso.\n\n\n\n              Abril 2000, Ecografía: discreto crecimiento de lesión hepática a PAAF: negativa.\n     Consulta de Endocrinología y Nutrición (seguimiento). Evaluación ambulatoria posto-\n     peratoria4 .\n     EXPLORACIÓN FÍSICA: talla 180,5 cm, peso 65,5 kg, BMI 20,1.\n     Peso habitual 82 kg (BMI 25,2). % pérdida de peso 20%.\n     Actividad física mínima (camina algo a diario). 1-2 deposiciones con esteatorrea.\n\n\n\n150\n---\nANALÍTICA: Hb 12,5 GOT 91, GPT 98, GGT 143, Alb 2,9, HbA1c 7,8.\nEn tratamiento con insulina basal, enzimas pancreáticos y suplementos específicos de\ndiabetes, dos envases al día (410 kcal y 18,4 gr de proteínas).\nSe añade suplementos con MCT (80ml).\n\n\n\n         Continuación del seguimiento: mayo 2000:                persiste imagen de 13 mm en ECO\n¿posible infección en resolución? RNM sin alteraciones significativas.\n\n\n\n         Agosto 2000: gammagrafía con octreótide: negativa.\n\n\n\n         Noviembre 2000: RNM: lesión 1 cm en lóbulo hepático izquierdo y otras menores\nsugerentes de metástasis.\n\n\n\n         Febrero 2001, RMN: 2 imágenes de aspecto metastásico en segmento IV (1-2 cm)\ny lóbulo derecho central (1’5 cm).\n\n\n\n         Marzo 2001 PET:       metástasis hepáticas segmento IV y lóbulo derecho junto con\nlesiones prevertebrales izquierdas.\n\n\n\n         Abril 2001: gammagrafia con octreótide confirma la captación hepática y adeno-\npatías peripancreáticas.\nTratamiento tras recidiva.\n\n\n\n         16/4/2001: inicia nuevamente a dosis plenas DTIC 500 mg + 5FU 1000 mg iv d1-5\ncada 3 semanas, x 3 ciclos hasta junio 2001 (último con reducción de dosis 20% de\n5FU x toxicidad: diarrea G2, mucositis G3) con resultado de Enfermedad Estable y se\ndesestima rescate quirúrgico.\n\n\n\n         Septiembre 2001: se administra IFN 3 Millones 3 días por semana. A los 2 meses\nel paciente decide suspender dicho tratamiento. por toxicidad inaceptable.\n\n\n\n         14/1/2002: PROGRESIÓN RADIOLÓGICA (2 nuevas LOES hepáticas más pequeñas)\npero asintomático.\nInicia nueva línea QT ESTREPTOZOTOCINA 900 mg d1-5/6 semanas + ADRIAMICINA\n90 mg iv d1/ 3 semanas recibiendo 3 ciclos de ETZ y 6+2 de ADR hasta junio 2002 mejor\ntolerancia (náuseas/vómitos G1, diarrea G1).\nResultado: Enfermedad Estable (3 mx en RNM de 2, 1 y 0´8 cm\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}